Cybin Inc (CYBN) - Total Assets
Based on the latest financial reports, Cybin Inc (CYBN) holds total assets worth CA$290.11 Million CAD (≈ $209.86 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Cybin Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cybin Inc - Total Assets Trend (2020–2025)
This chart illustrates how Cybin Inc's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Cybin Inc for net asset value and shareholders' equity analysis.
Cybin Inc - Asset Composition Analysis
Current Asset Composition (March 2025)
Cybin Inc's total assets of CA$290.11 Million consist of 64.2% current assets and 35.8% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 52.2% |
| Accounts Receivable | CA$5.88 Million | 2.3% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$41.02 Million | 15.9% |
| Goodwill | CA$51.49 Million | 19.9% |
Asset Composition Trend (2020–2025)
This chart illustrates how Cybin Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Cybin Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cybin Inc's current assets represent 64.2% of total assets in 2025, a decrease from 95.9% in 2020.
- Cash Position: Cash and equivalents constituted 52.2% of total assets in 2025, down from 90.3% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 19.9% of total assets.
Cybin Inc Competitors by Total Assets
Key competitors of Cybin Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Cybin Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.78 | 12.60 | 13.57 |
| Quick Ratio | 13.78 | 12.60 | 13.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$206.72 Million | CA$154.38 Million | CA$61.58 Million |
Cybin Inc - Advanced Valuation Insights
This section examines the relationship between Cybin Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.03 |
| Latest Market Cap to Assets Ratio | 1.17 |
| Asset Growth Rate (YoY) | -14.4% |
| Total Assets | CA$258.62 Million |
| Market Capitalization | $301.37 Million USD |
Valuation Analysis
Above Book Valuation: The market values Cybin Inc's assets above their book value (1.17x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Cybin Inc's assets decreased by 14.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cybin Inc (2020–2025)
The table below shows the annual total assets of Cybin Inc from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | CA$258.62 Million ≈ $187.08 Million |
-14.37% |
| 2024-03-31 | CA$302.02 Million ≈ $218.48 Million |
+460.37% |
| 2023-03-31 | CA$53.90 Million ≈ $38.99 Million |
-35.88% |
| 2022-03-31 | CA$84.06 Million ≈ $60.81 Million |
-8.74% |
| 2021-03-31 | CA$92.11 Million ≈ $66.63 Million |
+5283.52% |
| 2020-03-31 | CA$1.71 Million ≈ $1.24 Million |
-- |
About Cybin Inc
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anx… Read more